Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
share announcement

Feature Review Papers on Gastroesophageal Junction and Gastric Cancers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (17 April 2023) | Viewed by 17142

Special Issue Editor

Prof. Dr. Caroline Gronnier

E-Mail Website
Guest Editor
Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, 33600 Pessac, France
Interests: esophageal cancer; esophageal adenocarcinoma; esophageal squamous cell carcinoma; surgery; chemoradiotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer of the stomach and esophageal junction is one of the most frequent causes of cancer deaths around the world. This is due to a late diagnosis at the metastatic stage but also to resistance to classical chemotherapies. Peri-operative chemotherapy is the reference treatment for resectable gastric and esophageal cancers. In recent years, research has been marked by the classification of gastric cancer based on molecular subtypes, which opens the possibility of personalized therapy. Targeted therapies have recently emerged that focus on microsatellite instability, human epidermal growth factor receptor 2, programmed cell death ligand 1, and Epstein–Barr virus. Only a small proportion of patients with these cancers are eligible for targeted therapies. In addition, many new signaling pathways involved in gastric cancer have been identified in recent years, and the esogastric junction constitutes a potential lead for new target therapies. Research is particularly active in the field of immunotherapy and targeting of cancer stem cells. 

The objective of this Special Issue is to collect journal review articles that provide the latest news on gastric and esogastric cancer.

Prof. Dr. Caroline Gronnier
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastroesophageal junction and gastric cancers

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

5 pages, 224 KiB  
Editorial
Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
by Caroline Gronnier
Cancers 2022, 14(16), 3979; https://doi.org/10.3390/cancers14163979 - 17 Aug 2022
Cited by 1 | Viewed by 1403
Abstract
Gastric cancer is the fifth most common cancer in the world and the third leading cause of cancer deaths [...] Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)

Review

Jump to: Editorial

13 pages, 2822 KiB  
Review
Gastro-Esophageal Junction Precancerosis: Histological Diagnostic Approach and Pathogenetic Insights
by Cinzia Giacometti, Anna Gusella and Mauro Cassaro
Cancers 2023, 15(24), 5725; https://doi.org/10.3390/cancers15245725 - 06 Dec 2023
Viewed by 979
Abstract
Barrett’s esophagus (BE) was initially defined in the 1950s as the visualization of gastric-like mucosa in the esophagus. Over time, the definition has evolved to include the identification of goblet cells, which confirm the presence of intestinal metaplasia within the esophagus. Chronic gastro-esophageal [...] Read more.
Barrett’s esophagus (BE) was initially defined in the 1950s as the visualization of gastric-like mucosa in the esophagus. Over time, the definition has evolved to include the identification of goblet cells, which confirm the presence of intestinal metaplasia within the esophagus. Chronic gastro-esophageal reflux disease (GERD) is a significant risk factor for adenocarcinoma of the esophagus, as intestinal metaplasia can develop due to GERD. The development of adenocarcinomas related to BE progresses in sequence from inflammation to metaplasia, dysplasia, and ultimately carcinoma. In the presence of GERD, the squamous epithelium changes to columnar epithelium, which initially lacks goblet cells, but later develops goblet cell metaplasia and eventually dysplasia. The accumulation of multiple genetic and epigenetic alterations leads to the development and progression of dysplasia. The diagnosis of BE requires the identification of intestinal metaplasia on histologic examination, which has thus become an essential tool both in the diagnosis and in the assessment of dysplasia’s presence and degree. The histologic diagnosis of BE dysplasia can be challenging due to sampling error, pathologists’ experience, interobserver variation, and difficulty in histologic interpretation: all these problems complicate patient management. The development and progression of Barrett’s esophagus (BE) depend on various molecular events that involve changes in cell-cycle regulatory genes, apoptosis, cell signaling, and adhesion pathways. In advanced stages, there are widespread genomic abnormalities with losses and gains in chromosome function, and DNA instability. This review aims to provide an updated and comprehensible diagnostic approach to BE based on the most recent guidelines available in the literature, and an overview of the pathogenetic and molecular mechanisms of its development. Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)
►▼ Show Figures

Graphical abstract

14 pages, 1198 KiB  
Review
A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma
by Styliani Mantziari, Penelope St Amour, Francesco Abboretti, Hugo Teixeira-Farinha, Sergio Gaspar Figueiredo, Caroline Gronnier, Dimitrios Schizas, Nicolas Demartines and Markus Schäfer
Cancers 2023, 15(5), 1628; https://doi.org/10.3390/cancers15051628 - 06 Mar 2023
Cited by 3 | Viewed by 2386
Abstract
Gastric adenocarcinoma remains associated with a poor long-term survival, despite recent therapeutical advances. In most parts of the world where systematic screening programs do not exist, diagnosis is often made at advanced stages, affecting long-term prognosis. In recent years, there is increasing evidence [...] Read more.
Gastric adenocarcinoma remains associated with a poor long-term survival, despite recent therapeutical advances. In most parts of the world where systematic screening programs do not exist, diagnosis is often made at advanced stages, affecting long-term prognosis. In recent years, there is increasing evidence that a large bundle of factors, ranging from the tumor microenvironment to patient ethnicity and variations in therapeutic strategy, play an important role in patient outcome. A more thorough understanding of these multi-faceted parameters is needed in order to provide a better assessment of long-term prognosis in these patients, which probably also require the refinement of current staging systems. This study aims to review existing knowledge on the clinical, biomolecular and treatment-related parameters that have some prognostic value in patients with gastric adenocarcinoma. Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)
►▼ Show Figures

Figure 1

15 pages, 837 KiB  
Review
Role of Exosomes and Their Potential as Biomarkers in Epstein-Barr Virus-Associated Gastric Cancer
by Binnari Kim and Kyoung-Mee Kim
Cancers 2023, 15(2), 469; https://doi.org/10.3390/cancers15020469 - 12 Jan 2023
Cited by 6 | Viewed by 2158
Abstract
Exosomes are a subtype of extracellular vesicles ranging from 30 to 150 nm and comprising many cellular components, including DNA, RNA, proteins, and metabolites, encapsulated in a lipid bilayer. Exosomes are secreted by many cell types and play important roles in intercellular communication [...] Read more.
Exosomes are a subtype of extracellular vesicles ranging from 30 to 150 nm and comprising many cellular components, including DNA, RNA, proteins, and metabolites, encapsulated in a lipid bilayer. Exosomes are secreted by many cell types and play important roles in intercellular communication in cancer. Viruses can hijack the exosomal pathway to regulate viral propagation, cellular immunity, and the microenvironment. Cells infected with Epstein-Barr virus (EBV), one of the most common oncogenic viruses, have also been found to actively secrete exosomes, and studies on their roles in EBV-related malignancies are ongoing. In this review, we focus on the role of exosomes in EBV-associated gastric cancer and their clinical applicability in diagnosis and treatment. Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)
►▼ Show Figures

Figure 1

13 pages, 708 KiB  
Review
Secondary Primary Cancer after Primary Gastric Cancer: Literature Review and Big Data Analysis Using the Health Insurance Review and Assessment Service (HIRA) Database of Republic of Korea
by Jeong Ho Song, Yeonkyoung Lee, Jaesung Heo, Sang-Yong Son, Hoon Hur and Sang-Uk Han
Cancers 2022, 14(24), 6165; https://doi.org/10.3390/cancers14246165 - 14 Dec 2022
Cited by 2 | Viewed by 1596
Abstract
Advances in cancer screening and early detection, as well as improvements in surgical techniques and therapeutics, have contributed to decreasing gastric cancer mortality. The number of gastric cancer survivors continues to rise; however, long-term follow-up has revealed an increase in the risk of [...] Read more.
Advances in cancer screening and early detection, as well as improvements in surgical techniques and therapeutics, have contributed to decreasing gastric cancer mortality. The number of gastric cancer survivors continues to rise; however, long-term follow-up has revealed an increase in the risk of post-gastrectomy symptoms or other health problems, such as extra-gastric secondary primary cancer (SPC), in these survivors. Therefore, evidence-based screening for new primary cancer is needed in these populations; however, the incidence of SPC varies by country or continent and its characteristics have not been clearly reported. The characteristics of SPC are of increasing interest to both treatment providers and gastric cancer survivors; thus, this literature review explores not only the epidemiology and biology of SPC but also clinical and biological factors that influence its prognosis. Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)
►▼ Show Figures

Figure 1

15 pages, 695 KiB  
Review
Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
by Kole H. Buckley, Blake A. Niccum, Kara N. Maxwell and Bryson W. Katona
Cancers 2022, 14(23), 5953; https://doi.org/10.3390/cancers14235953 - 01 Dec 2022
Cited by 10 | Viewed by 4724
Abstract
Carriers of a pathogenic germline variant (PV) in BRCA1 or BRCA2 are at increased risk for a number of malignancies, including breast, ovarian, pancreatic, and prostate cancer. In this review, we discuss emerging evidence that BRCA2 PV carriers, and likely also BRCA1 PV [...] Read more.
Carriers of a pathogenic germline variant (PV) in BRCA1 or BRCA2 are at increased risk for a number of malignancies, including breast, ovarian, pancreatic, and prostate cancer. In this review, we discuss emerging evidence that BRCA2 PV carriers, and likely also BRCA1 PV carriers, are also at increased risk for gastric cancer (GC), highlighting that GC may be part of the BRCA1/2 cancer risk spectrum. While the pathogenesis of GC among BRCA1/2 PV carriers remains unclear, increasing evidence reveals that GCs are often enriched with mutations in homologous recombination-associated genes such as BRCA1/2, and that GC prognosis and response to certain therapies can depend on BRCA1/2 expression. Given the strength of data published to date, a risk management strategy for GC among BRCA1/2 PV carriers is needed, and herein we also propose a potential strategy for GC risk management in this population. Moving forward, further study is clearly warranted to define the mechanistic relationship between BRCA1/2 PVs and development of GC as well as to determine how GC risk management should be factored into the clinical care of BRCA1/2 carriers. Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)
►▼ Show Figures

Figure 1

27 pages, 2194 KiB  
Review
Hippo in Gastric Cancer: From Signalling to Therapy
by Lornella Seeneevassen, Pierre Dubus, Caroline Gronnier and Christine Varon
Cancers 2022, 14(9), 2282; https://doi.org/10.3390/cancers14092282 - 03 May 2022
Cited by 10 | Viewed by 3059
Abstract
The Hippo pathway is one of the most important ones in mammals. Its key functions in cell proliferation, tissue growth, repair, and homeostasis make it the most crucial one to be controlled. Many means have been deployed for its regulation, since this pathway [...] Read more.
The Hippo pathway is one of the most important ones in mammals. Its key functions in cell proliferation, tissue growth, repair, and homeostasis make it the most crucial one to be controlled. Many means have been deployed for its regulation, since this pathway is not only composed of core regulatory components, but it also communicates with and regulates various other pathways, making this signalisation even more complex. Its role in cancer has been studied more and more over the past few years, and it presents YAP/TAZ as the major oncogenic actors. In this review, we relate how vital this pathway is for different organs, and how regulatory mechanisms have been bypassed to lead to cancerous states. Most studies present an upregulation status of YAP/TAZ, and urge the need to target them. A focus is made here on gastric carcinogenesis, its main dysregulations, and the major strategies adopted and tested to counteract Hippo pathway disbalance in this disease. Hippo pathway targeting can be achieved by various means, which are described in this review. Many studies have tested different potential molecules, which are detailed hereby. Though not all tested in gastric cancer, they could represent a real interest. Full article
(This article belongs to the Special Issue Feature Review Papers on Gastroesophageal Junction and Gastric Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop